Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 10, 2014; 5(5): 1036-1047
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1036
Genomic era diagnosis and management of hereditary and sporadic colon cancer
Edward David Esplin, Michael Paul Snyder
Edward David Esplin, Michael Paul Snyder, Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, United States
Author contributions: Esplin ED and Snyder MP contributed to this paper.
Supported by The Child Health Research Institute and the Stanford CTSA, No. UL1 TR000093
Correspondence to: Edward David Esplin, MD, PhD, Clinical Scholar, Department of Genetics, Stanford University School of Medicine, 300 Pasteur Dr., Alway M302, Stanford, CA 94305, United States.
Telephone: +1-650-7239914 Fax: +1-650-7251534
Received: January 27, 2014
Revised: March 21, 2014
Accepted: May 16, 2014
Published online: December 10, 2014
Core Tip

Core tip: The era of genomic sequencing is beginning to make significant impact on the diagnosis and management of sporadic and inherited colorectal adenocarcinoma (CRC) such as familial adenomatous polyposis. This review will discuss the current guidelines for diagnosis and management of CRC and how genomic sequencing is enabling earlier definitive diagnosis with associated intensive surveillance and preventative interventions, molecular tumor characterization directing tumor specific therapy, germline patient genome analysis which informs individual drug tolerance and efficacy, and is evolving to develop post-treatment surveillance, with the potential to ultimately decrease the current prevalence and mortality of CRC, sporadic and hereditary.